Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before

Changes in Cognition and Amyloid-β Processing with Long Term Cholesterol Reduction using Atorvastatin in Aged Dogs

(2017) M. Paul Murphy et al.   JOURNAL OF ALZHEIMERS DISEASE

Alzheimer's disease

(2011) Clive Ballard et al.   LANCET

Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift

(2011) Todd E. Golde et al.   NEURON

A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease

(2010) Ronald S. Black et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease☆

(2010) D. Allan Butterfield et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Methylene Blue Reduces Aβ Levels and Rescues Early Cognitive Deficit by Increasing Proteasome Activity

(2010) David X. Medina et al.   BRAIN PATHOLOGY

Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid β After a Single Administration of an Amyloid β Monoclonal Antibody in Subjects With Alzheimer Disease

(2010) Eric R. Siemers et al.   CLINICAL NEUROPHARMACOLOGY

Drug Profile: Transdermal Rivastigmine Patch in the Treatment of Alzheimer Disease

(2010) Murat Emre et al.   CNS Neuroscience & Therapeutics

Effects of Rivastigmine Transdermal Patch and Capsule on Aspects of Clinical Global Impression of Change in Alzheimer’s Disease: A Retrospective Analysis

(2010) Jeffrey L. Cummings et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Alzheimer Disease

(2010) Rudy J. Castellani et al.   DM DISEASE-A-MONTH

Disposition and Metabolism of Semagacestat, a  -Secretase Inhibitor, in Humans

(2010) P. Yi et al.   DRUG METABOLISM AND DISPOSITION

Bapineuzumab

(2010) Geoffrey A Kerchner et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts

(2010) S. J. Cano et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Oxidative Stress in the Progression of Alzheimer Disease in the Frontal Cortex

(2010) Mubeen A. Ansari et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

(2010) Juha O Rinne et al.   LANCET NEUROLOGY

Alzheimer's failure raises questions about disease-modifying strategies

(2010) Andy Extance   NATURE REVIEWS DRUG DISCOVERY

Alzheimer's disease: strategies for disease modification

(2010) Martin Citron   NATURE REVIEWS DRUG DISCOVERY

Mechanisms of AD neurodegeneration may be independent of Aβ and its derivatives

(2010) Nikolaos K. Robakis   NEUROBIOLOGY OF AGING

Are Aβ and Its Derivatives Causative Agents or Innocent Bystanders in AD?

(2010) Nikolaos K. Robakis   Neurodegenerative Diseases

Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe

(2010) H. H. Feldman et al.   NEUROLOGY

Acyclovir or Aβ42 peptides attenuate HSV-1-induced miRNA-146a levels in human primary brain cells

(2010) Walter J. Lukiw et al.   NEUROREPORT

Early Alzheimer's Disease

(2010) Richard Mayeux   NEW ENGLAND JOURNAL OF MEDICINE

Alzheimer's Disease

(2010) Henry W. Querfurth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: A novel mechanism of action

(2010) Eugenio Barone et al.   PHARMACOLOGICAL RESEARCH

Dimebon disappointment

(2010) Roy W Jones   Alzheimers Research & Therapy

Non-apolipoprotein E and apolipoprotein E genetics of sporadic Alzheimer's disease

(2009) Davide Seripa et al.   AGEING RESEARCH REVIEWS

Mechanism of cytotoxicity mediated by the C31 fragment of the amyloid precursor protein

(2009) Sun Ah Park et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Roles of Nicotinic Receptors in Acetylcholinesterase Inhibitor-Induced Neuroprotection and Nicotinic Receptor Up-Regulation

(2009) Yuki Takada-Takatori et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects

(2009) Alain Patat et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Rivastigmine Transdermal Patch Skin Tolerability

(2009) Jeffrey L. Cummings et al.   CLINICAL DRUG INVESTIGATION

Memantine

(2009) Kate McKeage   CNS DRUGS

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer’s disease: a post hoc analysis

(2009) Martin R. Farlow et al.   CURRENT MEDICAL RESEARCH AND OPINION

Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials

(2009) Bengt Winblad et al.   CURRENT MEDICAL RESEARCH AND OPINION

Optimal Dosing of Galantamine in Patients with Mild or Moderate Alzheimerʼs Disease

(2009) Stephen Aronson et al.   DRUGS & AGING

Memantine versus donepezil in mild to moderate Alzheimer’s disease: a randomized trial with magnetic resonance spectroscopy

(2009) P. J. Modrego et al.   EUROPEAN JOURNAL OF NEUROLOGY

In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid β-peptide of APP

(2009) D. Allan Butterfield et al.   FREE RADICAL BIOLOGY AND MEDICINE

Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials

(2009) C. H. Sadowsky et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32)

(2009) Jason T. Olin et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer DiseaseA Randomized Controlled Trial

(2009) Robert C. Green   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

 -Amyloid Monomers Are Neuroprotective

(2009) M. L. Giuffrida et al.   JOURNAL OF NEUROSCIENCE

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

(2009) S. Salloway et al.   NEUROLOGY

Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: Role of lipid peroxidation in Alzheimer's disease pathogenesis

(2009) Marzia Perluigi et al.   Proteomics Clinical Applications

Glutamate-based antidepressants: 20 years on

(2009) Phil Skolnick et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer Disease

(2008) Adam S. Fleisher et al.   ARCHIVES OF NEUROLOGY

NAP and D-SAL: neuroprotection against the β amyloid peptide (1–42)

(2008) Illana Gozes et al.   BMC NEUROSCIENCE

High- and low-calcium-dependent mechanisms of mitochondrial calcium signalling

(2008) A SPAT et al.   CELL CALCIUM

Donepezil Treatment of Severe Alzheimer’s Disease in Nursing Home Settings. A Responder Analysis

(2008) Vesna Jelic et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Therapeutic potential of CERE-110 (AAV2-NGF): Targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons

(2008) Kathie M. Bishop et al.   EXPERIMENTAL NEUROLOGY

Pharmacological treatment in moderate-to-severe Alzheimer's disease

(2008) Ging-Yuek Robin Hsiung et al.   EXPERT OPINION ON PHARMACOTHERAPY

Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer's disease

(2008) J. Greilberger et al.   FREE RADICAL RESEARCH

Proteomic identification of nitrated brain proteins in early Alzheimer’s disease inferior parietal lobule

(2008) Tanea T. Reed et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer's Disease

(2008) Y. Matsuoka et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

(2008) Rachelle S Doody et al.   LANCET

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial

(2008) Gordon K Wilcock et al.   LANCET NEUROLOGY

Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial

(2008) Alistair Burns et al.   LANCET NEUROLOGY

Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

(2008) Ganesh M Shankar et al.   NATURE MEDICINE

Redox proteomic identification of 4-Hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: Insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease

(2008) Tanea Reed et al.   NEUROBIOLOGY OF DISEASE

Antibody Capture of Soluble Aβ Does Not Reduce Cortical Aβ Amyloidosis in the PDAPP Mouse

(2008) Peter Seubert et al.   Neurodegenerative Diseases

Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis

(2008) Scott A. Small et al.   NEURON

Effect of R3487/MEM3454, a novel nicotinic α7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats

(2008) Amir H. Rezvani et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease

(2008) Ilya Bezprozvanny et al.   TRENDS IN NEUROSCIENCES

Loss of phospholipid asymmetry and elevated brain apoptotic protein levels in subjects with amnestic mild cognitive impairment and Alzheimer disease

(2007) Miranda L. Bader Lange et al.   NEUROBIOLOGY OF DISEASE